Literature DB >> 35034965

PD-L1 interacts with Frizzled 6 to activate β-catenin and form a positive feedback loop to promote cancer stem cell expansion.

Lingchen Fu1, Jia Fan2,3, Sudipa Maity2,3, Grant McFadden1,4, Yixin Shi5,6, Wei Kong7.   

Abstract

Cancer stem cells (CSCs) drive tumor initiation, progression, metastasis, and drug resistance. We report here that programmed cell death ligand 1 (PD-L1) is constitutively expressed in cancer cells to maintain and expand CSC through a novel mechanism in addition to promoting cancer cell immune evasion. We discovered that PD-L1 interacts with receptor Frizzled 6 to activate β-catenin signaling and increase β-catenin-targeted gene expression, such as a putative stem cell marker leucine-rich-repeat-containing G-protein-coupled receptor 5. Blockage of PD-L1 function, using a specific small hairpin RNA or a specific antibody, inhibits disease progression by reducing the CSC population in both colorectal and breast tumors. Moreover, β-catenin conversely regulates PD-L1 expression through a β-catenin complex binding site in the PD-L1 promoter. Our discoveries reveal that besides assistant tumor cell immune escaping, PD-L1 and β-catenin signaling form a positive feedback loop to promote cancer progression through CSC maintenance and expansion.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35034965     DOI: 10.1038/s41388-021-02144-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

2.  Malignant lymphoma originating from the earliest T-lineage precursor cell.

Authors:  Y Hashimoto; M Yasukawa; K Takada; T Hato; S Fujita
Journal:  Am J Hematol       Date:  1993-08       Impact factor: 10.047

3.  Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.

Authors:  L Vermeulen; M Todaro; F de Sousa Mello; M R Sprick; K Kemper; M Perez Alea; D J Richel; G Stassi; J P Medema
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

4.  Crypt stem cells as the cells-of-origin of intestinal cancer.

Authors:  Nick Barker; Rachel A Ridgway; Johan H van Es; Marc van de Wetering; Harry Begthel; Maaike van den Born; Esther Danenberg; Alan R Clarke; Owen J Sansom; Hans Clevers
Journal:  Nature       Date:  2008-12-17       Impact factor: 49.962

5.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

Authors:  Matilde Todaro; Mileidys Perez Alea; Anna B Di Stefano; Patrizia Cammareri; Louis Vermeulen; Flora Iovino; Claudio Tripodo; Antonio Russo; Gaspare Gulotta; Jan Paul Medema; Giorgio Stassi
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

6.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

7.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

8.  Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Authors:  Daniel J Pearce; David Taussig; Catherine Simpson; Kirsty Allen; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

9.  High-fat diet enhances stemness and tumorigenicity of intestinal progenitors.

Authors:  Semir Beyaz; Miyeko D Mana; Jatin Roper; Dmitriy Kedrin; Assieh Saadatpour; Sue-Jean Hong; Khristian E Bauer-Rowe; Michael E Xifaras; Adam Akkad; Erika Arias; Luca Pinello; Yarden Katz; Shweta Shinagare; Monther Abu-Remaileh; Maria M Mihaylova; Dudley W Lamming; Rizkullah Dogum; Guoji Guo; George W Bell; Martin Selig; G Petur Nielsen; Nitin Gupta; Cristina R Ferrone; Vikram Deshpande; Guo-Cheng Yuan; Stuart H Orkin; David M Sabatini; Ömer H Yilmaz
Journal:  Nature       Date:  2016-03-03       Impact factor: 49.962

10.  SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma.

Authors:  Takayuki Kawai; Kentaro Yasuchika; Takamichi Ishii; Yuya Miyauchi; Hidenobu Kojima; Ryoya Yamaoka; Hokahiro Katayama; Elena Yukie Yoshitoshi; Satoshi Ogiso; Sadahiko Kita; Katsutaro Yasuda; Ken Fukumitsu; Junji Komori; Etsuro Hatano; Yoshiya Kawaguchi; Shinji Uemoto
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more
  4 in total

1.  Silencing PLOD2 attenuates cancer stem cell-like characteristics and cisplatin-resistant through Integrin β1 in laryngeal cancer.

Authors:  Meiyan Song; Xing Liu; Tao Li; Yueqin Zhang; Xiaoyan Zhao; Wen Sun; Zhen Li
Journal:  Transl Oncol       Date:  2022-06-03       Impact factor: 4.803

Review 2.  Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications.

Authors:  Lei Wang; Zeng Jin; Rohan P Master; Chandra K Maharjan; Madison E Carelock; Tiffany B A Reccoppa; Myung-Chul Kim; Ryan Kolb; Weizhou Zhang
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  WNT signaling and cancer stemness.

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Essays Biochem       Date:  2022-09-16       Impact factor: 7.258

4.  Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer.

Authors:  Yunxia Ma; Rumyana Marinkova; Miljana Nenkov; Lai Jin; Otmar Huber; Jürgen Sonnemann; Natália Peca; Nikolaus Gaßler; Yuan Chen
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.